Table 3.
Demographic and clinicopathological characteristics of patients with PDA (n=67)
| Characteristic | n (%) |
|---|---|
| Age, years, median (range) | 64 (39–83) |
| Sex | |
| Female | 34 (50.7) |
| Male | 33 (49.3) |
| Tumour site | |
| Body/tail | 9 (13.6) |
| Head | 57 (86.4) |
| Jaundice | 48 (71.6) |
| Weight loss | 41 (63.1) |
| Abdominal pain | 28 (41.8) |
| Preoperative diabetes | 15 (22.4) |
| BMI, median (range) | 28.4 (15.2–48.1) |
| Smoking (pack-years), median (range) | 10 (0–100) |
| Alcohol use | |
| Low/moderate | 60 (90.9) |
| Heavy | 6 (9.1) |
| Serum CA19-9, median (range) | 156 (0–8691) |
| Total bilirubin, median (range) | 4.4 (0.2–29.7) |
| Alkaline phosphatase, median (range) | 305 (48–3629) |
| Tumour size, cm, median (range) | 2.5 (0.5–10) |
| Clinical stage (AJCC8) | |
| IA | 3 (4.5) |
| IB | 10 (14.9) |
| IIA | 1 (1.5) |
| IIB | 34 (50.7) |
| III | 19 (28.4) |
| IV | 0 (0) |
| Tumour grade | |
| Well (G1) | 11 (17.5) |
| Moderate (G2) | 33 (52.4) |
| Poor (G3) | 19 (30.1) |
| Lymph node metastases present | 19 (28.4) |
| Perineural invasion present | 37 (56.1) |
| Angiolymphatic invasion present | 31 (46.3) |
| Common bile duct extension present | 25 (37.3) |
| Peripancreatic extension present | 56 (83.6) |
| Duodenal extension present | 35 (52.2) |
| Neoadjuvant treatment | 12 (17.9) |
AJCC8, American Joint Committee on Cancer 8th edition cancer staging manual; BMI, body mass index; CEA, carcinoembryonic antigen; PDA, pancreatic ductal adenocarcinoma.